KYVERNA THERAPEUTICS, INC.

Press Releases Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
12.53 ^USD	+1.70%		-3.62%	-.--%

14/05	Kyverna Therapeutics Q1 Loss Narrows	MT
14/05	Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	15/05	PR
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1	01/04	AQ
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med	30/03	PR
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results	27/03	PR
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis	08/03	PR
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares	13/02	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer